GSK to invest USD 1.2bn in infectious disease battle

GSK Plc plans to invest GBP 1bn (USD 1.2bn) over a decade to accelerate work on new medicines and vaccines to combat malaria, tuberculosis, HIV, neglected tropical diseases and antibiotic resistance.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA publishes new plan to support antibiotic development
For subscribers